Wall Street Zen upgraded shares of Smith & Nephew SNATS (NYSE:SNN – Free Report) from a hold rating to a buy rating in a research report released on Sunday,Wall Street Zen reports.
SNN has been the subject of a number of other reports. Bank of America lowered shares of Smith & Nephew SNATS from a “buy” rating to a “neutral” rating in a research note on Tuesday, September 8th. Zacks Research cut shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a report on Thursday, November 5th. Barclays downgraded shares of Smith & Nephew SNATS from an “equal weight” rating to an “underweight” rating in a research note on Wednesday, August 5th. BTIG Research assumed coverage on shares of Smith & Nephew SNATS in a report on Monday, August 31st. They set a “neutral” rating on the stock. Finally, Berenberg Bank set a $33.88 price target on shares of Smith & Nephew SNATS in a report on Friday, September 11th. One analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Reduce” and a consensus price target of $31.91.
Check Out Our Latest Research Report on Smith & Nephew SNATS
Smith & Nephew SNATS Price Performance
NYSE SNN opened at $31.23 on Friday. Smith & Nephew SNATS has a 12 month low of $26.12 and a 12 month high of $37.09. The stock’s fifty day moving average price is $28.73 and its 200-day moving average price is $30.99. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.14 and a quick ratio of 1.11.
Institutional Trading of Smith & Nephew SNATS
Large investors have recently made changes to their positions in the stock. Parallel Advisors LLC raised its position in shares of Smith & Nephew SNATS by 20.0% during the 1st quarter. Parallel Advisors LLC now owns 2,322 shares of the medical equipment provider’s stock valued at $74,000 after buying an additional 387 shares in the last quarter. Clearstead Trust LLC bought a new position in shares of Smith & Nephew SNATS in the 2nd quarter valued at about $25,000. Versant Capital Management Inc grew its position in Smith & Nephew SNATS by 7.9% in the third quarter. Versant Capital Management Inc now owns 8,852 shares of the medical equipment provider’s stock worth $239,000 after acquiring an additional 647 shares in the last quarter. Addison Advisors LLC purchased a new position in Smith & Nephew SNATS in the second quarter worth about $43,000. Finally, Allworth Financial LP purchased a new position in Smith & Nephew SNATS in the second quarter worth about $48,000. 25.64% of the stock is currently owned by institutional investors.
About Smith & Nephew SNATS
Smith & Nephew plc is a global medical technology company that develops and sells products used in surgery, orthopaedics and wound care. Its offerings include implants for hip and knee replacement, instruments and devices for sports medicine and ear, nose and throat procedures, and products designed to manage wounds and support tissue repair. Founded in 1856 in Hull, England, the company began as a pharmacy business before expanding into medical products. It now serves healthcare providers and patients in markets around the world.
Recommended Stories
- Five stocks we like better than Smith & Nephew SNATS
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Smith & Nephew SNATS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew SNATS and related companies with MarketBeat.com's FREE daily email newsletter.
